tbuckley/cabot-search huggingface dataset:
THE RELATION EXISTING BETWEEN BRIGHT'S DISEASE AND CERTAIN EAR SYMPTOMS.
Authors: FRANCIS DOWLING
Journal: JAMA (1898)

During the past year a limited number of cases of ear affections have come under my observation where there were certain well marked symptoms such as tinnitus aurium, dull aching pain referred to the region of the mastoid, more or less reduction of the hearing power, slight irregularity in the gait, etc., where there were no appreciable pathologic conditions of the structures of the ear as far as could be ascertained. In most of the cases the patients were of large fleshy build and over-fed appearance and examination of the urine showed the presence of more or less albumin. I present two cases for discussion as to whether there was not a possible connection between the ear symptoms and the organic disease of the kidneys. <h3>Case 1.</h3> —Benjamin B., aged 50, a plumber, consulted me March 4, 1893, complained of dull aching pain in the region of the mastoid. The
Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer's disease paired helical filament tau
Authors: Eriko S. Matsuo, Ryong-Woon Shin, Melvin L. Billingsley, Andre Van deVoorde, Michael O'Connor, John Q. Trojanowski, Virginia M.Y. Lee
Journal: Neuron (1994)
Abstract 3501: Flavopiridol decreases Mcl-1 and XIAP in acute myeloid leukemia cell resulting in augmentation of sorafenib-induced apoptosis
Authors: Lijuan Xia, Janice Gabrilove, Yongkui Jing
Journal: Cancer Research (2011)

Abstract The PI3K/AKT/mTOR and Raf/MEK/ERK pathways, resulting in increased levels of Mcl-1, XIAP and survivin, have been found to be activated in acute myeloid leukemia cells (AML) due to the mutant receptor tyrosine kinases. FMS-like tyrosine kinase (FLT3) mutations including FLT3-internal tandem duplication (FLT3-ITD) are found in about 30% of cases of acute myeloid leukemia and confer an increased relapse rate and reduced overall survival. Sorafenib, inhibiting Raf-1 of the MAPK pathway resulting in diminished MEK and ERK phosphorylation, is being tested in AML patients with FLT3-ITD and modest responses have been observed: similarly flavopiridol, a CDK and mRNA transcription inhibitor, has been tested in AML patients with some evidence of activity. We hypothesize that sorafenib plus flavopiridol will have enhanced therapeutic effects. The combined apoptotic effects of sorafenib plus flavopiridol were investigated in HL-60, MV4;11 FLT3-ITD+ cells, as well as in primary leukemic cells isolated from AML patients. Sorafenib and flavopiridol indepedently induced apoptosis at 10 μM and 200 nM, respectively, in HL-60 cells which was correlated with the down-regulation of Mcl-1, XIAP and/or survivin. The combination of sorafenib (5 μM) plus flavopiridol (100 nM) produced augmented apoptosis associated with enhanced diminution in levels of Mcl-1. MV4;11 cells were more sensitive than HL-60 cells to sorafenib-induced apoptosis, but not to flavopiridol, with the down-regulation of Mcl-1 and survivin. Addition of flavopiridol to MV4;11 cells enhanced sorafenib-induced apoptosis with augmented down-regulation of XIAP. Primary cells isolated from two AML patients with FLT3-ITD+ cells exhibited augmented apoptosis induction with the combination treatment of sorafenib plus flavopiridol. Our data suggest that the augmented apoptosis induction in AML cells by sorafenib plus flavopiridol is mediated by decreasing levels of complimentary anti-apoptotic proteins. This novel combination therapy is worthy of a clinical trial in FLT3-ITD+ AML patients. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3501. doi:10.1158/1538-7445.AM2011-3501
Dynamic mechanisms in human coronary stenosis.
Authors: B G Brown, E L Bolson, H T Dodge
Journal: Circulation (1984)

At the clinical level, coronary stenoses frequently behave as though the obstruction to flow were variable and not as rigidly fixed as previously imagined. Pressure (energy) lost in flow through a stenosis is the primary determinant of its hemodynamic impact. Ischemic episodes occur when pressure distal to the stenosis falls below that needed to perfuse the subendocardium. Three important properties of the stenosis contribute to variation in its pressure loss. First, loss is proportional to the square of stenosis flow. Thus proper distribution of perfusion is doubly vulnerable to conditions such as exercise, anemia, or pharmacologic vasodilation, which ordinarily increase myocardial blood flow. Second, pressure loss is proportional to the inverse fourth power of minimum lumen diameter. As a result, seemingly small changes in diameter are amplified to large changes in stenosis resistance. Third, a compliant arc of normal arterial wall borders part of the lumen in the majority of coronary lesions. This extremely important morphologic feature of stenoses permits transient variation in stenosis lumen diameter in response to drugs or to variation in endogenous vasomotor activity or intraluminal pressure. Although our understanding is incomplete, many of the clinical features of coronary disease and its pharmacologic responses are explained in terms of these stenosis properties and their interaction.
Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane
Authors: Maria Rius, Anne T. Nies, Johanna Hummel-Eisenbeiss, Gabriele Jedlitschky, Dietrich Keppler
Journal: Hepatology (2003)

The liver is the major source of reduced glutathione (GSH) in blood plasma. The transport protein mediating the efflux of GSH across the basolateral membrane of human hepatocytes has not been identified so far. In this study we have localized the multidrug resistance protein 4 (MRP4; ABCC4) to the basolateral membrane of human, rat, and mouse hepatocytes and human hepatoma HepG2 cells. Recombinant human MRP4, expressed in V79 hamster fibroblasts and studied in membrane vesicles, mediated ATP–dependent cotransport of GSH or S –methyl–glutathione together with cholyltaurine, cholylglycine, or cholate. Several monoanionic bile salts and the quinoline derivative MK571 were potent inhibitors of this unidirectional transport. The K m values were 2.7 mmol/L for GSH and 1.2 mmol/L for the nonreducing S –methyl–glutathione in the presence of 5 μmol/L cholyltaurine, and 3.8 μmol/L for cholyltaurine in the presence of 5 mmol/L S –methyl–glutathione. Transport of bile salts by MRP4 was negligible in the absence of ATP or without S –methyl–glutathione. These findings identify a novel pathway for the efflux of GSH across the basolateral hepatocyte membrane into blood where it may serve as an antioxidant and as a source of cysteine for other organs. Moreover, MRP4–mediated bile salt transport across the basolateral membrane may function as an overflow pathway during impaired bile salt secretion across the canalicular membrane into bile. In conclusion, MRP4 can mediate the efflux of GSH from hepatocytes into blood by cotransport with monoanionic bile salts.
What Does It Take for Primary Care Practices to Truly Deliver Behavioral Health Care?
Authors: Lloyd I. Sederer
Journal: JAMA Psychiatry (2014)

In what may be the largest state government behavioral health endeavor nationally, New York State (NYS) is more than midway into a federally supported initiative to fully integrate behavioral health care into ambulatory, primary care resident training sites, beginning with selected academic medical centers (AMCs). This is not simply to detect and refer, nor to colocate medical and mental health services under the same roof or down the hall from each other; it is the integration of behavioral health care, starting with adults with depression, into the standard operations of the primary care practice—no different from how these practices serve people with diabetes mellitus, asthma, or cardiovascular diseases. The goal, over time, is statewide dissemination. In this Viewpoint, I describe the circumstances and the interagency partnership that permitted this initiative to be launched (ie, its essential elements, its tough implementation challenges, and what must be done for sustainability).
The multilayer nanoparticles formed by layer by layer approach for cancer-targeting therapy
Authors: Keun Sang Oh, Hwanbum Lee, Jae Yeon Kim, Eun Jin Koo, Eun Hee Lee, Jae Hyung Park, Sang Yoon Kim, Kwangmeyung Kim, Ick Chan Kwon, Soon Hong Yuk
Journal: Journal of Controlled Release (2012)
First Derivative of the Electrocardiogram
Authors: Paul H. Langner, David B. Geselowitz
Journal: Circulation Research (1962)

A method for obtaining the first derivative of the ECG electronically has been described and the curve of the first derivative displayed with the original ECG. It has been demonstrated that the first derivative emphasizes the high frequency components of the ECG and firmly establishes the fact that these are very real and significant components of the ECG. The ultimate usefulness of this method in electrocardiographic diagnosis remains to be determined.
Tc-99m MIBI Scintigraphy in Tall Cell Variant of Papillary Thyroid Carcinoma With Negative Radioiodine Scan
Authors: Meryem Kaya, Tevfik Fikret Çermik
Journal: Clinical Nuclear Medicine (2008)

We report on a 45-year-old man who had a mass on the wall of the anterior right hemithorax. An excisional biopsy indicated carcinoma metastasis from thyroid malignancy. Tc-99m methoxyisobutyl isonitrile (MIBI) scintigraphy revealed markedly increased activity on the left side of the thyroid and the thoracic wall mass. Postoperative histology revealed a tall cell variant of papillary thyroid carcinoma. Whole body scintigraphy after radioiodine treatment was negative twice. However, Tc-99m MIBI and bone scintigraphy showed multiple soft tissue and bone metastases in the follow-up period. He died 3 years later because of complications of distant lung metastases.
Classifying Systolic and Diastolic Heart Failure
Authors: Viorel G. Florea
Journal: JAMA (2007)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Sodium-Potassium Pump in Low-Renin Hypertension
Authors: FRANCIS J. HADDY
Journal: Annals of Internal Medicine (1983)

Recent studies suggest that sodium-dependent low-renin hypertension in animals results at least in part from sodium-potassium pump inhibition in blood vessels and heart by a humoral agent released from or influenced by the anteroventral third ventricular area of the brain. For example, a high salt intake in a rat with reduced renal mass results in the appearance of a heat-stable sodium pump inhibitor in the plasma, decreased cardiac Na+, K+-ATPase activity, decreased arterial sodium-potassium pump activity, and hypertension. These changes are reversed by reducing the salt intake or by producing a lesion in the anteroventral third ventricular area of the brain. The course of the development of pump inhibition is similar to the course of the development of hypertension. Sodium-potassium pump inhibition by a humoral agent may also occur in humans with low-renin hypertension. A high potassium intake may stimulate pump activity.
Behavioral effects of neural grafts: Action still in search of a mechanism
Authors: Michael L. Woodruff
Journal: Behavioral and Brain Sciences (1995)

Abstract This commentary reviews data supporting circuitry reconstruction, replacement neurotransmitters, and trophic action as mechanisms whereby transplants promote recovery of function. Issue is taken with the thesis of Sinden et al. that adequate data exist to indicate that reconstruction of hippocampal circuitry damaged by hypoxia with CA1 transplants is a confirmed mechanism whereby these transplants produce recovery. Sinden et al.'s and Stein &amp; Glasier's proposal that there is definitive evidence showing that all transplants produce trophic effects is also questioned.
Strategies To Increase Detection of Hemochromatosis
Authors: Sharon M. McDonnell
Journal: Annals of Internal Medicine (1998)

As part of the Iron Overload, Public Health and Genetics conference, sponsored by the Centers for Disease Control and Prevention in March 1997, a working group was convened to consider strategies to increase early case detection of hemochromatosis.This group emphasized that the primary public health goal should be to diagnose hemochromatosis before symptoms appear. To reach this goal, education and action need to be targeted to physicians and other health care workers, laboratorians, administrators, payers, and the public. Strategies to disseminate updated information and increase early case detection were prioritized according to expected effectiveness.Strategies targeting physicians are 1) to identify national and local physician-leaders and 2) to educate physicians about hemochromatosis in basic, graduate specialty, and continuing medical education. Strategies aimed at the health system are 1) to encourage laboratories to provide the transferrin saturation test as part of routine laboratory panels and 2) to work with policymakers and payers to allow reimbursement for case detection. Finally, public education is recommended to increase lay support for the early diagnosis of hemochromatosis. Attempts to educate the public should be aimed first at persons who receive diagnoses of hemochromatosis in order to ensure that they are properly treated and then at asymptomatic persons who could be screened as part of health appraisals. Although identifying physician-leaders and educating physicians are the highest priorities, physicians should not be targeted at the exclusion of payers and the public. Simultaneous efforts to reach all groups in appropriate ways should be initiated to provide the interest and infrastructure necessary to decrease morbidity and mortality from hemochromatosis.
Preparation of the Skin For Lumbar Puncture
Authors: James A. Visconti
Journal: JAMA (1969)

To the Editor:—  We would like to call attention to Skin Preparation for Lumbar Puncture: Ether or Soap? (208:1196, 1969). Dr. Harvey Bernard, MD, of the Albany Medical College replied to the question concerning the use ofhexachlorophene(Septisol) followed by benzalkonium chloride for skin preparation before lumbar puncture. We would like to submit the following additional information concerning the skin cleansing procedure.  Benzalkonium (Zephiran) chloride, along with benzathonium ( Phemerol) chloride, and cetylpyridium ( Ceepryn) chloride are quanternary ammonium cationic surface-acting agents and germicides. When these germicides come in contact with anionic soaps, as are found in hexachlorophene ( Septisol and Phisohex), the large organic ions of opposite charges are attracted to one another, and decrease or destroy the bacteriostatic activity of the cationic surface-acting germicides.1,2  When surfaces have been washed with soap they must be thoroughly rinsed with water to remove any residual soap before applying a quanternary ammonium
M ANTIGENS AMONG GROUP A STREPTOCOCCI ISOLATED FROM SKIN LESIONS
Authors: Franklin H. Top, Lewis W. Wannamaker, W. R. Maxted, Bascom F. Anthony
Journal: The Journal of Experimental Medicine (1967)

Three new provisional types of Group A streptococci have been identified among strains isolated from skin infections of American Indian children. A previously established type, Type 41, was also recognized among the pyoderma strains. Most of the skin streptococci with T-agglutination pattern 3/13/B3264 could be identified as Type 41 or as one of two new provisional types, Schoenborn (Type 52) and Hanson (proposed Type 53). Strains of the third new provisional type, Kingbird (proposed Type 54), agglutinated as 15/17/19/23/47, a T pattern not associated with skin infections in studies of other populations. Approximately half of the pyoderma strains examined were found to produce an M antigen; the proportion of M-typable strains from skin infections was found to be similar to that currently found in throat cultures of children with pharyngitis. The demonstration of M antigens in streptococci from skin lesions provides evidence of their potential virulence and should facilitate their classification in subsequent epidemiological studies.
Physical Activity Counseling for Healthy Adults as a Primary Preventive Intervention in the Clinical Setting
Authors: Sally S. Harris
Journal: JAMA (1989)

Physical activity has been associated with the prevention and control of several medial conditions that are major causes of death and disability in the United States. The criterion-based approach adopted by the US Preventive Services Task Force is used to objectively evaluate the evidence regarding the effectiveness of physical activity counseling for healthy adults as a primary preventive intervention in the clinical setting. This evaluation addresses: (1) the burden of suffering attributable to physical inactivity; (2) the efficacy of physical activity in disease prevention in regard to six medical conditions; and (3) the characteristics of the intervention in terms of simplicity, cost, safety, acceptability, and patient compliance. Based on consideration of the evidence for each of these issues, specific recommendations are made regarding the role of physical activity counseling in routine clinical practice. In addition, practical guidelines are presented to aid clinicians in physical activity counseling.
The RAD51-Stimulatory Compound RS-1 Can Exploit the RAD51 Overexpression That Exists in Cancer Cells and Tumors
Authors: Jennifer M. Mason, Hillary L. Logan, Brian Budke, Megan Wu, Michal Pawlowski, Ralph R. Weichselbaum, Alan P. Kozikowski, Douglas K. Bishop, Philip P. Connell
Journal: Cancer Research (2014)

RAD51 is the central protein that catalyzes DNA repair via homologous recombination, a process that ensures genomic stability. RAD51 protein is commonly expressed at high levels in cancer cells relative to their noncancerous precursors. High levels of RAD51 expression can lead to the formation of genotoxic RAD51 protein complexes on undamaged chromatin. We developed a therapeutic approach that exploits this potentially toxic feature of malignancy, using compounds that stimulate the DNA-binding activity of RAD51 to promote cancer cell death. A panel of immortalized cell lines was challenged with the RAD51-stimulatory compound RS-1. Resistance to RS-1 tended to occur in cells with higher levels of RAD54L and RAD54B, which are Swi2/Snf2-related translocases known to dissociate RAD51 filaments from dsDNA. In PC3 prostate cancer cells, RS-1-induced lethality was accompanied by the formation of microscopically visible RAD51 nuclear protein foci occurring in the absence of any DNA-damaging treatment. Treatment with RS-1 promoted significant antitumor responses in a mouse model, providing proof-of-principle for this novel therapeutic strategy.
Mason named CDC director
Authors: Marsha F. Goldsmith
Journal: JAMA (1983)

A record of devotion to disease prevention, health promotion, and health services research characterizes the career of James O. Mason, MD, DrPH, who was named last month to succeed William H. Foege, MD, MPH, as director of the Centers for Disease Control (CDC), Atlanta. Mason has been executive director of the Utah Department of Health since 1979. The move to Atlanta in December will be a return to professional roots for Mason, who is 53. A medical officer of the US Public Health Service for 11 years, he served as chief of the CDC's Epidemic Intelligence Service (1959), Hepatitis Surveillance Unit (1960), and Surveillance Section (1961), as well as deputy director of the Bureau of Laboratories (1964-1968) and of the entire CDC (1969-1970). Announcing Mason's appointment as CDC head, US Department of Health and Human Services Secretary Margaret Heckler said, "We have replaced quality with quality.... Dr Foege's decision to
MASA syndrome is due to mutations in the neural cell adhesion gene L1CAM
Authors: Lieve Vits, Guy Van Camp, Paul Coucke, Erik Fransen, Kristel De Boulle, Edwin Reyniers, Bernhard Korn, Annemarie Poustka, Golder Wilson, Connie Schrander-Stumpel, Robin M. Winter, Charles Schwartz, Patrick J. Willems
Journal: Nature Genetics (1994)
AMERICAN STANDARD INSURANCE CORPORATION
Authors: Ramsay Spillman
Journal: JAMA (1935)

<h3>To the Editor:—</h3> The American Standard Insurance Corporation of Indianapolis is circularizing New York physicians with a letter beginning "Will you accept our Physicians' Noncancellable Full Lifetime Income Policy for TWO FULL WEEKS—at our risk and expense?" It should interest all physicians receiving this circular material to know that the New York<i>Medical Week</i>for Nov. 10, 1934, published a report on this company's financial status as of Dec. 31, 1933, obtained from the Indiana State Insurance Department by Dr. A. M. Rabiner of Brooklyn. Prospective clients looking forward to full lifetime non-cancellable income policy will judge for themselves as to the resources backing up these promises: <h3>Comment.—</h3> A large number of requests have been received for information concerning the American Standard Insurance Corporation of Indianapolis. When one compares the financial standing of the American Standard Insurance Corporation, with no capital, admitted assets of something over $6,000 and liabilities
P1137 TREATMENT OF CHRONIC HCV GENOTYPE 1 (G1) INFECTION WITH BOCEPREVIR IN GERMAN REAL-LIFE: HIGH EFFICACY TOGETHER WITH MODERATE TREATMENT DISCONTINUATION RATES IN TREATMENT-NAIVE PATIENTS
Authors: P. Buggisch, H. Löhr, G. Teuber, H. Steffens, M.R. Kraus, C. John, P.R. Geyer, B. Weber, T. Witthöft, A. Herrmann, M. Hoesl, U. Naumann, T. Dahhan, D. Hartmann, B. Dreher, M. Bilzer
Journal: Journal of Hepatology (2014)
Many NHS trusts are not ready for statutory registration, regulator warns
Authors: C. White
Journal: BMJ (2009)

Poor compliance with safety standards means that many NHS trusts will not be ready for statutory registration when it starts next year, England’s regulator of health and adult social care services, the Care Quality Commission, has warned.

From April 2010 all NHS healthcare organisations in England, to continue treating patients, will be legally required to register with the commission.

Speaking at the Risk and Patient Safety 2009 conference in London on 24 November, Danny Keenan, the commission’s national clinical adviser, said that healthcare organisations would still be assessed against themes “very similar” …
IMPACT OF MYOCARDIAL BRIDGING ON MAJOR ADVERSE CARDIAC EVENTS: VERY LONG–TERM CLINICAL OUTCOMES FOLLOWING FIRST– AND SECOND–GENERATION DRUG–ELUTING STENT IMPLANTATION
Authors: Ryotaro Yamada, Kenji Sakamoto, Hideki Kitahara, Paul Yock, Peter Fitzgerald, Yasuhiro Honda
Journal: Journal of the American College of Cardiology (2013)